Acadia Pharmaceuticals Inc., of San Diego, reported that net third-quarter sales of Nuplazid, (pimavanserin), to treat hallucinations and delusions associated with Parkinson's disease psychosis, were $58.3 million, an increase of 64 percent, as compared to $35.6 million reported for the three months ended Sept. 30, 2017.